Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Asset disposition
Employment agrmnt
Consulting agrmnt
Appointed director
Tonix Pharmaceuticals Holding Corp. (TNXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin for the Treatment of Pain"
09/29/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PLACEMENT AGENT AGREEMENT",
"FORM OF PRE-FUNDED WARRANT",
"FORM OF COMMON WARRANT",
"FORM OF SERIES B COMMON WARRANT",
"OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP",
"OPINION OF LOWENSTEIN SANDLER LLP",
"FORM OF SECURITIES PURCHASE AGREEMENT",
"Tonix Pharmaceuticals Announces Proposed Public Offering",
"Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering"
09/29/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
09/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/27/2023 8-K Quarterly results
08/21/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact",
"Corporate Presentation by the Company for August 2023"
08/16/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
08/10/2023 8-K Quarterly results
Docs: "Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights",
"CORPORATE PRESENTATION BY THE COMPANY FOR AUGUST 2023"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION BY THE COMPANY FOR AUGUST 2023"
08/07/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID"
08/01/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/28/2023 8-K Quarterly results
07/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of KPMG LLP"
07/26/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/18/2023 8-K/A Quarterly results
07/17/2023 8-K Quarterly results
07/12/2023 8-K Quarterly results
07/10/2023 8-K Quarterly results
07/03/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Fin...
Docs: "TRANSITION SERVICES AGREEMENT",
"Zembrace® SymTouch® : IMPORTANT SAFETY INFORMATION Zembrace SymTouch can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:",
"Corporate Presentation by the Company for July 2023"
06/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/07/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress",
"Fc - Modified Anti - CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications Ryo Otsuka, Grace Lassiter, Takayuki Hirose, Ahmad Karadagi , Toshihide Tomosugi , Ivy Rosales, Tatsuo Kawai Center for Transplantation Sciences Massachusetts General Hospital, Boston, MA, USA Ryo Otsuka, PhD Research Fellow Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, USA I have no financial relationships with commercial interests to disclose. AND My presentation does not include discussion of off - label or investigational use.",
"Efficacy Of CD154 Blockade With TNX - 1500 To Prevent Heart Allograft Immune Injury I. Ileka 1 , K. Kinoshita 1 , R. Chaban 1 , G. McGrath 1 , Z. Habibabady 1 , C. Miller 1 , J. O 1 , S. Landino 1 , J. Nawalaniec 1 ,S. Fogarty 2 , B. Daugherty 2 , S. Lederman 2 , J. C. Madsen 1 , R. N. Pierson III 1 1 Center for Transplantation Sciences, Massachusetts General Hospital, Boston MA 2 Tonix Pharmaceuticals Inc., Chatham, NJ, USA",
"Tonix Pharmaceuticals Holding Corp. 8-K"
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION BY THE COMPANY FOR JUNE 2023"
05/31/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 at the 2023 American Transplant Congress"
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement"
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Confidential Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology Annual Meeting"
05/23/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Announces the Isolation and Characterization of the -Isomer of Tianeptine, TNX-4300 , Now Under Development for Psychiatric and Neurodegenerative Diseases"
05/17/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression",
"TNX-601 PRODUCT PRESENTATION"
05/09/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Change of Tonix Pharmaceuticals Holding Corp., and effective May 10, 2023",
"Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy